Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaprazole dual versus quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2400086862Phase 4Completed
- Sponsor
- Beijing Huaxin Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ilaprazole, amoxicillin, clarithromycin and bismuth subcitrate in Helicobacter pylori infection (3 arms), sponsored by Beijing Huaxin Hospital. Primary endpoint: Helicobacter pylori eradication rate. Started Jul 2024; status: completed.
02
Drugs
ilaprazoleamoxicillinclarithromycinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400086862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086862.